Highest-materiality recent filing
Keen Vision Acquisition receives Nasdaq delisting notice; trading suspended Aug 3, 2026
Received Nasdaq notice on July 27, 2026 for non-compliance with SPAC 36-month deadline and minimum public float/holders rules.
KVAC shareholders approve extension to July 2027; 935,966 shares redeemed
Shareholders approved extending business combination deadline up to four additional three-month periods to July 27, 2027, with $30,000 deposit per extension.
Keen Vision Acquisition enters binding LOI for $100M merger with Novoheart
LOI replaces prior Sept 2024 Merger Agreement, which was terminated via mutual release.
At January 22, 2026 annual meeting, shareholders approved extending the business combination period up to two additional three-month periods to July 27, 2026.
Keen Vision extends business combination deadline to July 2025; 8.5M shares redeemed
Shareholders approved extending the business combination deadline from Oct 27, 2024 to July 27, 2025 via monthly $200k deposits.
Keen Vision Acquisition Corp. to merge with Medera Inc. in deal valued at $622.6M
Medera valued at $622.56M; each Acquirer Ordinary Share valued at $10.00.
On March 13, 2024, the Board appointed CHU, William as a director of the Board, including committee positions as a member on the Audit Committee and the Compensation Committee, and as Chairman on the Nominating Committee, effective immediately.
On March 13, 2024, Professor LI, Ronald Adolphus resigned from his positions as a director of the board of directors (the “ Board ”) of the Keen Vision Acquisition Corporation (the “ Company ”), including from his committee positions on the Audit Committee, Compensation Committee, and the Nominating Committee, effective immediately.
Max materiality 0.85 · Median 0.50 · Most common event other_material